|Bid||130.55 x 900|
|Ask||130.69 x 1100|
|Day's Range||128.82 - 131.65|
|52 Week Range||115.03 - 217.25|
|Beta (5Y Monthly)||1.69|
|PE Ratio (TTM)||11.15|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for MRNALearn more
Key Insights Institutions' substantial holdings in Moderna implies that they have significant influence over the...
In this article, we will be taking a look at 10 stocks Jim Cramer and hedge funds have in common. To see more of these stocks, you can go directly to see 5 Stocks Jim Cramer and Hedge Funds Have In Common. “If You Use NVIDIA’s Chips, You Can Speak In The Vernacular Of ChatGPT” […]
The AI in healthcare market is expected to top $100 billion by the end of the decade, and some companies are already leveraging this technology to advance their work. Two great examples are Moderna (NASDAQ: MRNA) and Doximity (NYSE: DOCS). Moderna isn't a novice when it comes to AI.
Is Moderna stock a buy after the company reported a 19-cent gain in the first quarter vs. calls for losses? Is MRNA stock a buy?
The number of people with COVID-19 has been rising rapidly in China in recent weeks, and there are concerns that the government in Beijing could consider reviving its strict lockdown policies again. COVID-19 cases have been surging in China, largely due to the spread of the omicron XBB variants. In February, the Centers for Disease Control and Prevention pointed to early study results showing that for the bivalent vaccine boosters created to target omicron variants, "[vaccine effectiveness] was generally similar against BA.5-related infections [original omicron] and XBB/XBB.1.5-related infections."
OVER $300 BILLION That's how much has been wiped off the combined market value of [Moderna](https://www.wsj.com/market-data/quotes/MRNA), [Pfizer](https://www.wsj.com/market-data/quotes/PFE) and [BioNTech](https://www.
Moderna Pfizer and its partner BioNTech are among the biggest losers in the healthcare sector this year, dropping more than 25% each. The declines have been driven by a sense that, as the Covid-19 emergency enters the rearview mirror, demand for boosters will continue to wane. Just last week, the European Commission cut the number of vaccines it is purchasing from Pfizer and BioNTech.
Artificial intelligence (AI) could change the way we treat and prevent illnesses, which makes it a highly valuable opportunity for companies. In fact, the global AI healthcare market is set to reach more than $100 billion later this decade, a Markets and Markets report shows. Two perfect examples are biotech Moderna (NASDAQ: MRNA) and medical device giant Medtronic (NYSE: MDT).
With its stock down 8.4% over the past week, it is easy to disregard Moderna (NASDAQ:MRNA). However, a closer look at...
You'd have a lot more money, but only if you resisted the temptation to take the initial profits.
Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.
U.S. vaccine maker Moderna said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy. The U.S. pharmaceutical and biotech firm registered a unit called Moderna (China) Biotech Limited in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha. "We are exploring opportunities to engage in the market and bring the power of Moderna’s mRNA platform to the people of China," a spokesperson said in response to a query from Reuters.
BEIJING (Reuters) -Vaccine maker Moderna Inc said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy. The U.S. biotech firm registered a unit called Moderna (China) Biotech Ltd in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha. "We are exploring opportunities to engage in the market and bring the power of Moderna's mRNA platform to the people of China," a company spokesperson said in response to a query from Reuters.
Three years since the pandemic upended the economy, here are the Massachusetts public companies that made it through in the best — and worst — shape.
The fact that multiple Moderna, Inc. ( NASDAQ:MRNA ) insiders offloaded a considerable amount of shares over the past...
Insider buying, or the legal, reported purchase of shares in a company by its C-suite/board members/large shareholders, is considered a bullish signal. However, does that mean it is best to sell/avoid stocks insiders are selling? Put simply, it depends. Heavy insider selling, or even a lack of insider buying, can sometimes be a sign that those most “in the know” at a company are not very confident in its future prospects. Then again, much like with “outsider” investors, lack of confidence isn’t
A life sciences company in Durham has secured a major partnership to discover new gene therapy treatments.
The Moving Average Convergence Divergence (MACD) oscillator is below the zero line telling us that MRNA lacks trend strength. In this daily Point and Figure chart of MRNA, below, I can see a potential upside price target in the $179 area. This weekly Point and Figure chart of MRNA, below, shows us the same $179 price target as the daily chart above.
Yahoo Finance Live discusses a drop in shares of Moderna after a report of a resurgence of Covid in China.
Biotech giant Moderna (NASDAQ: MRNA) made a name for itself in the past couple of years as it developed and marketed one of the most successful coronavirus vaccines. Demand for coronavirus vaccines has started to fall, affecting Moderna's revenue. Is Moderna's stock worth considering, especially at current levels?
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The good news is you really don't have to -- and you still can win in the stock market. The success of Moderna's (NASDAQ: MRNA) blockbuster coronavirus vaccine helped the stock soar earlier in the pandemic. Here's why they shouldn't: The vaccine represents just the beginning of Moderna's growth story.
Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.
These biotech stocks are swinging for the fences. They may hit homers, they may strike out. But you’ll definitely want to watch them. Biotech stocks have been a high risk, high reward proposition in recent years. Many biotech companies soared high during the pandemic only to crash hard in its aftermath. We now search through the wreckage to see which will soar again, and which are best left for dead. For an investor who wants stability and low risk, there are plenty of big biotech stocks out the
Biotech investors love to take on oodles of risk in hopes of getting an outsized reward when one of their bets finally pays off. While NHPs account for only 0.5% of the animal models used in biomedicine, biotechs and other researchers in the U.S. have faced a shortage of NHPs since at least 2019.